Moxetumomab pasudotox (MoP), a recombinant immunoglobulin linked to a Pseudomonas exotoxin targeting CD22, was initially developed as a treatment for relapsed or refractory HCL. The gene discussed is CD22; the disease is hairy cell leukemia.